India, May 16 -- Neurocrine Biosciences, Inc. (NBIX) Friday announced new encouraging data from a Phase 4 study of Ingrezza in patients with tardive dyskinesia, a neurological disorder characterized by involuntary movements.
The analyses were conducted using data from patients who participated in a Phase 4 withdrawal study. Patients in the study received Ingrezza for eight weeks, after which they were randomized to either continue Ingrezza or receive placebo for an additional eight weeks.
New data from the study showed that patients with tardive dyskinesia who received continued treatment with Ingrezza demonstrated improvements across functional and health-related quality of life (HRQoL) measures.
googletag.cmd.push(function() { googleta...